Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Ionis Pharmaceuticals Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
IONS
Nasdaq
8731
https://www.ionispharma.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Ionis Pharmaceuticals Inc
Ionis Publishes 2023 Corporate Responsibility Report
- Apr 25th, 2024 11:00 am
Ionis to hold first quarter 2024 financial results webcast
- Apr 23rd, 2024 11:05 am
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
- Apr 7th, 2024 1:48 pm
Ionis to present at upcoming investor conferences
- Apr 1st, 2024 11:05 am
Ionis to hold olezarsen Phase 3 data webcast
- Mar 28th, 2024 11:05 am
Can Ionis' (IONS) Wholly-Owned Drugs Cut Dependency on Collabs?
- Mar 25th, 2024 1:09 pm
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
- Mar 25th, 2024 12:18 pm
Ionis Pharmaceuticals (IONS) Down 2.8% Since Last Earnings Report: Can It Rebound?
- Mar 22nd, 2024 3:30 pm
New Blood Thinners Will Prevent Blood Clots Without Causing Bleeding
- Mar 21st, 2024 7:00 pm
30 Biggest Biotechnology Companies in the World
- Mar 17th, 2024 12:50 pm
Ionis (IONS) Drug Meets Mid-Stage MASH Study Goals
- Mar 14th, 2024 2:40 pm
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
- Mar 13th, 2024 11:00 am
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
- Mar 6th, 2024 12:30 pm
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
- Feb 29th, 2024 2:05 pm
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Just Released Its Yearly Results And Analysts Are Updating Their Estimates
- Feb 24th, 2024 1:00 pm
Ionis Pharmaceuticals Full Year 2023 Earnings: Beats Expectations
- Feb 23rd, 2024 10:36 am
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Q4 2023 Earnings Call Transcript
- Feb 22nd, 2024 3:59 pm
Ionis (IONS) Q4 Loss Narrower Than Expected, Sales Surge Y/Y
- Feb 22nd, 2024 3:29 pm
Q4 2023 Ionis Pharmaceuticals Inc Earnings Call
- Feb 22nd, 2024 7:20 am
Ionis Pharmaceuticals Inc (IONS) Surpasses Revenue Guidance for 2023, Sets Sights on 2024 Growth
- Feb 21st, 2024 4:31 pm
Scroll